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Abstract
Objective: To assess demographic, clinical, magnetic resonance imaging, and
treatment exposure predictors of time to 3 or 12-month confirmed disability
worsening in clinically isolated syndrome (CIS) and early multiple sclerosis
(MS). Methods: We utilized the MSBase Incident Study (MSBasis), a prospec-
tive cohort study of outcome after CIS. Predictors of time to first 3 and 12-
month confirmed expanded disability status scale worsening were analyzed
using Cox proportional hazards regression. Results: About 1989 patients were
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analyzed, the largest seen-from-onset cohort reported to-date. A total of 391
patients had a first 3-month confirmed disability worsening event, of which 307
were sustained for 12 months. Older age at CIS onset (adjusted hazard ratio:
aHR 1.17, 95% 1.06, 1.30), pyramidal (aHR 1.45, 95% CI 1.13, 1.89) and
ambulation (HR 1.60, 95% CI 1.09, 2.34) system dysfunction, annualized
relapse rate (aHR 1.20, 95% CI 1.18, 1.22), and lower proportion of observa-
tion time on treatment were associated with 3-month confirmed worsening.
Predictors of time to 12-month sustained worsening included pyramidal system
dysfunction (Hazard ratio: aHR 1.38, 95% CI 1.05, 1.83), and older age at CIS
onset (aHR 1.17, 95% CI 1.04, 1.31). Greater proportion of follow-up time
exposed to treatment was associated with greater reductions in the rate of wors-
ening. Interpretation: This study provides class IV evidence for a strong protec-
tive effect of disease-modifying treatment to reduce disability worsening events
in patients with CIS and early MS, and confirms age and pyramidal dysfunction
at onset as risk factors.
Introduction
Reduction in neurological disability is the most important
goal of early treatment in multiple sclerosis (MS). Reflect-
ing this, disability progression or “worsening” events have
been used as the primary endpoint in several recent
disease-modifying therapy (DMT) studies.1–3 The implicit
assumption is that therapeutic intervention in the relaps-
ing-remitting phase of MS reduces the incidence and rate
of accumulation of irreversible disability.
The Expanded Disability Status Scale (EDSS) is an ordi-
nal scale with 19 disease steps between 0 and 10. It is the
accepted gold standard for assessing level of disability and
worsening in MS clinical trials.4 In clinical trials, the identi-
fication of “confirmed disability worsening” is based on
assessment of repeated EDSS measurements. An increase
of 1 point on the EDSS above baseline subsequently
confirmed at repeat assessment either 3 or 6 months later
(3- or 6-month confirmed worsening) are commonly
used.1,5–10 However, the duration of a confirmed disability
worsening event is important, as some 3-month confirmed
disability worsening events later remit.11
A first confirmed EDSS disability worsening in clini-
cally isolated syndrome (CIS) and early MS heralds the
onset of MS-related disability. Prior data suggest that
DMT exposure in early MS reduces long-term disability
worsening in comparison to later exposure to DMT,12
but these results require confirmation. As randomized
clinical trials are typically of 2–3 years duration, their
capacity to measure long-term confirmed progression or
worsening rates are very limited. The aim of the current
study was to assess the independent effect of DMT expo-
sure on 3 month-confirmed (short-term) and 12-month
(long-term) sustained MS disability worsening events in a
large seen-from-onset cohort of patients, whilst control-
ling for putative demographic, clinical and magnetic reso-
nance imaging (MRI) predictors of these outcomes.
Patients and Methods
Study population and design
MSBasis is an observational cohort study based on prospec-
tively collected data, a substudy of the international
MSBase Registry.13,14 Patients who experienced a CIS and
were seen by a participating neurologist within 12 months
of onset were recruited into this longitudinal study.
MSBasis commenced in 2004 and, at date of data extrac-
tion, prospectively followed 3623 patients from MS special-
ist centers in 20 countries. Baseline data collected included
demographics, date of CIS, Kurtzke Functional System
(KFS) scores, and EDSS scores as well as cerebral MRI clas-
sification according to Barkhof-Tintore criteria. Follow-up
data collected at a minimum annually included: date of
visit, KFS/EDSS scores, relapses and treatment changes
since the patient’s last visit. Data entry was performed in or
near real time at most centers as previously described.15
Human research ethics committee approval was obtained
from the lead site (Melbourne Health HREC) and approv-
als or waivers, and written informed consent from patients
were obtained at each participating site, as local laws required.
Patients with a primary progressive disease course were
excluded from this study. A minimum of three visits per
patient spanning a minimum 9 months, with full EDSS
assessment was required to assess first confirmed 3-month
disability worsening. Patients without a complete baseline
KFS were excluded. Cerebral MRI was available for 88.0%
of patients within 12 months of first clinic visit. Of the
3623 patients enrolled in MSBasis at the time of data
extraction and compilation, 1989 patients were eligible
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for analysis following exclusions (largely inadequate fol-
low-up time, as the study continues to recruit). Differ-
ences between included and excluded patients were not
significant. For instance, 71.2% of eligible patients were
female compared to 67.8% of excluded patients. Median
age at onset was 32.9 years for eligible patients and
34.0 years in excluded patients.
Definitions
Disability worsening
Confirmed disability worsening events were defined as a
minimum one-point increase in EDSS score above a base-
line EDSS of between 1 and 5.5 confirmed at repeat assess-
ment at least 3 months or 1 year later. Baseline EDSS
scores of zero required a confirmed one and a half-point
increase, and baseline EDSS scores equal to or above six
required a half-point increase above baseline confirmed at
least 3 months or 1 year later. EDSS scores recorded
during relapses were excluded. Twelve-month sustained
worsening was defined as that subset of the initial 3-month
confirmed disability worsening who sustained this initial
worsening for a minimum of 12 months following the date
of the initial observed worsening.
Relapsing-remitting MS
As soon as MS is confirmed according to McDonald cri-
teria, iMed software (Merck Serono, Geneva, Switzerland)
classifies patients as relapsing-remitting MS (RRMS), this
includes “CIS patients” fulfilling “McDonald MS” and
those with clinically definite MS.
Baseline EDSS/KFS
Baseline EDSS and KFS here are derived from the EDSS
visit immediately preceding a 3- or 12-month confirmed
disability worsening event.
Baseline cerebral MRI
The T2 lesion load classifier was determined from the first
MRI scan recorded within 12 months of CIS onset (med-
ian 33 days; inter-quartile range [IQR] 9, 110), using the
Barkhof-Tintore categories of 0, 1–2, 3–8 or 9+ lesions.
Proportion of time on treatment
The proportion of time patients spent on treatment (PTT)
was used to account for changing treatment status of
patients over the observation period. It took into account
the total time a patient spent on treatment, including any
switches and gaps in treatment. All MS therapies were
included in the calculation of the PTT. The PTT was cen-
sored at confirmed worsening, or most recent visit if a wors-
ening event had not yet occurred. For the primary analysis,
PTT was categorized according to the following ranges: no
treatment (i.e., 0%), >0 to ≤50%, >50 to ≤80% and >80%.
No DMT
In the present study, no DMT refers to the patient group
that did not receive DMT treatment (IFNb, glatiramer
acetate, fingolimod, natalizumab) prior to first disability
worsening. This excludes the use of glucocorticoids to
treat relapses.
Statistical analyses
Categorical variables were summarized using frequency
and percentage and compared using Pearson’s v2. Contin-
uous variables were assessed for normality using a
Shapiro–Wilk test and described using mean and standard
deviation (SD), or summarized using median and IQR as
appropriate, and compared using one-way analysis of var-
iance (ANOVA), or Kruskal–Wallis with Bonferroni’s post
hoc correction respectively. Predictors of first 3-month
confirmed and 12-month sustained disability worsening
were assessed using univariable and multivariable Cox
proportional hazards regression. Hazard proportionality
was assessed through analysis of scaled Schoenfeld residu-
als. In the absence of a worsening event, data were cen-
sored at the most recent EDSS clinic visit. Demographic,
clinical, para-clinical, and treatment covariates that were
associated with the worsening outcome on univariable
analysis were then included in adjusted analyses. The
multivariable modeling analysis was adjusted for clinic
location (country) and sex. Interactions between model
covariates were examined in the multivariable modeling.
There were no significant interaction effects in the
adjusted models. To assess whether subjects recording
early worsening conferred an ascertainment bias upon the
association between treatment and subsequent worsening,
an additional model incorporating time from CIS onset to
initiation of first DMT as a predictor variable was run as a
sensitivity analysis. Kaplan–Meier survival curves were
plotted for worsening-free survival. All reported P-values
are exact and 2-tailed and for all analyses P < 0.05 was
considered significant. All analyses were performed using
Stata version 12.0 (StataCorp, College Station, TX).
Results
About 1989 CIS patients enrolled in MSBasis were
included in this analysis (Fig. 1). Table 1 summarizes
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baseline demographic, clinical, para-clinical, and treat-
ment characteristics of the cohort. A total of 6724 per-
son-years of follow-up were analyzed, with median
individual follow-up of 3.0 years (range 0.75–9.9). Mean
age at CIS onset was 32.8 years (SD 10.0) and 71.3% of
patients were female. Median EDSS at baseline was 1.5
(IQR: 1, 2), and 69% of patients with available MRI had
fewer than nine T2 lesions at baseline.
A total of 1339 (67.3%) of patients were exposed to at
least one DMT during the observation period. These
patients contributed 4895 person-years of follow-up of
which 3237 person-years were on therapy. Mean (SD) fol-
low-up was 3.4 years (2.2). Median time to first DMT
from CIS onset was 0.7 years (IQR: 0.4, 1.2) whilst mean
(SD) duration of first DMT (censoring at first worsening
event) was 2.2 years (1.5). Of these, 19% (n = 252) were
classified as CIS and 81% (n = 1087) of patients had
RRMS at the time of treatment initiation.
About 391 (19.7%) patients had a first 3-month con-
firmed disability worsening event. Of these, 307 (78.5%)
worsening events were sustained for at least 12 months.
Twenty-one patients’ disability worsening regressed, and
63 had insufficient follow-up to demonstrate sustained
worsening or regression, having been followed up for less
than the 12 months required to assess sustained worsening
at 12 months. Median (IQR) time to first 3-month con-
firmed disability worsening was 1.94 years (0.87, 3.39)
whilst median time to 12-month sustained worsening was
2.85 years (1.82, 4.22). On adjusted modeling (Table 2),
annualized relapse rate (ARR) was independently predic-
tive of increased rates of 3-month worsening (adjusted haz-
ard ratio [aHR] 1.20, 95% CI 1.18, 1.22) but not of 12-
month sustained worsening (aHR 1.01, 95% CI 0.98, 1.05).
Additionally a baseline ambulation KFS score of ≥1 versus
0 (aHR 1.60; 95% CI 1.09, 2.34), and a baseline pyramidal
KFS score of ≥2 versus 0–1 (aHR 1.45; 95% CI 1.13, 1.89)
were predictive of 3-month confirmed disability worsening
events. A baseline pyramidal score of ≥2 (vs. 0–1) remained
predictive (aHR 1.38; 95% CI 1.05, 1.83) of 12-month sus-
tained worsening. Older age at CIS onset was predictive of
both 3-month (aHR 1.17 per 10 years, 95% CI 1.06, 1.30)
and 12-month (HR 1.17 per 10 years, 95% CI 1.04, 1.31)
disability worsening events. Sex was not predictive of dis-
ease worsening on adjusted or unadjusted analyses.
Unadjusted modeling further revealed that a baseline
EDSS of 1–2.5 versus an EDSS of zero predicted an
Figure 1. Summary of patients analyzed in the present analysis. Note
the 12-month sustained disability worsening group is a subset of the
3-month confirmed disability worsening group.
Table 1. Baseline demographic and clinical characteristics.
Variable Level All patients (n = 1989)
Visits assessed Median (IQR) 7 (4, 11)
Range 3–66
Sex Male 571 (28.7%)
Female 1418 (71.3%)
Age at CIS Mean (SD) 32.9 (10.0)
Range 6–68
EDSS Median (IQR) 1.5 (1, 2)
Range 0–7.5
Affected KFS
(KFS score ≥1) Ambulation 208 (10.5%)
Pyramidal 1134 (57.0%)
Cerebellar 528 (26.5%)
Brainstem 634 (31.9%)
Sensory 943 (47.4%)
Bowel/Bladder 304 (15.3%)
Visual 485 (24.4%)
Mental 285 (14.3%)
T2 lesion load
0 77 (3.9%)
1–2 106 (5.3%)
3–8 1027 (51.6%)
≥9 540 (27.1%)
Not available 239 (12.0%)
Age at DMT
start (years)
Mean (SD) 33.2 (9.9)
Range 6.4–67.6
First DMT
(prior to worsening) No DMT 650 (32.7%)
IFNb-1a IM 373 (18.8%)
IFNb-1a SC 494 (24.8%)
IFNb-1b 232 (11.7%)
Glatiramer Acetate 208 (10.5%)
Fingolimod 4 (0.2%)
Natalizumab 28 (1.4%)
PTT
(censored at
progression)
0% 666 (33.5%)
>0–50% 349 (17.5%)
>50–80% 519 (26.1%)
>80% 455 (22.9%)
CIS, clinically isolated syndrome; EDSS, Expanded Disability Status
Scale; KFS, Kurtzke Functional System; DMT, disease-modifying ther-
apy; PTT, proportion of time on treatment; IQR, interquartile range;
IM, intramuscular; SC, subcutaneous.
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increased risk of 3-month (HR 2.34; 95% CI 1.72–3.28;
P < 0.001) and 12-month (HR 2.01; 95% CI 1.44–2.80;
P < 0.001) disability worsening events. Furthermore, an
EDSS of 3–5.5 as compared to an EDSS of zero was pre-
dictive of a greater risk of 3-month (HR 3.3; 95% CI
2.29–4.89; P < 0.001) and 12-month (HR 2.88; 95% CI
1.91–4.36; P < 0.001) worsening. However, EDSS and
KFS scores were highly correlated with each other and
thus were unable to be combined in the adjusted model
due to significant colinearity.
Although predictive on unadjusted analysis, the pres-
ence of nine or greater T2 lesions on baseline MRI was
not independently associated with increased risk of either
3-month confirmed (aHR 1.07, 95% CI 0.69, 1.68) or 12-
month sustained (aHR 0.98, 95% CI 0.61, 1.58) worsen-
ing in the multivariable models. A sensitivity analysis
showed that those patients with higher lesion load were
more likely to receive DMT earlier, and spent a greater
proportion of the observation period on DMT treatment
(Table 3).
The effect of treatment on risk of experiencing a dis-
ability worsening event was also assessed in the adjusted
regression model (Table 2). Mean (SD) duration of treat-
ment across the sample within the observation period
was 1.62 years (1.91) and 1.73 years (1.92) for the 3-
month confirmed and 12-month sustained worsening
analyses, respectively (where treatment duration was cen-
sored at the time of the initial first worsening event). The
median (IQR) number of DMT initiations per patient
were 1 (0, 1) for both the 3-month and 12-month analy-
ses. The cohort was sub-divided according to proportion
of time treated (PTT). Increasing PTT resulted in a step-
wise reduction in the rate of 3-month confirmed
(Fig. 2A) and 12-month sustained (Fig. 2B) worsening
Table 2. Predictors of 3-month confirmed and 12-month sustained disability worsening events.
Predictor Level
3-month confirmed worsening events
(n = 391)
12-month sustained worsening events
(n = 307)
n (% of level)
Adjusted HR
(95% CI) P-value1 n (% of level)
Adjusted HR
(95% CI) P-value2
Demographics
Sex Male 110 (19.3%) 1.05 (0.84, 1.31) 0.677 83 (14.5%) 0.97 (0.75, 1.25) 0.823
Female 281 (19.8%) 1.00 224 (15.8%) 1.00
Age at CIS onset Per 10 years – 1.17 (1.06, 1.30) 0.002 – 1.17 (1.04, 1.31) 0.007
Clinical
KFS ambulation 0 318 (17.9%) 1.00 254 (14.3%) 1.00
1+ 73 (35.1%) 1.60 (1.09, 2.34) 0.015 53 (25.5%) 1.45 (0.94, 2.22) 0.092
KFS pyramidal 0–1 242 (16.5%) 1.00 194 (13.2%) 1.00
2+ 149 (28.7%) 1.45 (1.13, 1.89) 0.003 113 (21.7%) 1.38 (1.05, 1.83) 0.023
KFS cerebellar 0–1 306 (18.5%) 1.00 243 (14.7%) 1.00
2+ 85 (25.6%) 1.06 (0.78, 1.44) 0.710 64 (19.3%) 1.33 (0.95, 1.86) 0.097
KFS bowel/bladder 0–1 342 (18.5%) 1.00 272 (14.8%) 1.00
2+ 49 (33.8%) 0.78 (0.52, 1.18) 0.246 35 (24.1%) 0.75 (0.47, 1.21) 0.241
Relapses
ARR – 1.20 (1.18, 1.22) <0.001 – 1.01 (0.98, 1.05) 0.456
MRI
T2 lesion load 0 27 (35.1%) 1.00 25 (32.5%) 1.00
1–2 26 (24.5%) 1.17 (0.67, 2.04) 0.578 22 (20.8%) 1.06 (0.59, 1.92) 0.834
3–8 195 (19.0%) 0.91 (0.60, 1.38) 0.649 148 (14.4%) 0.83 (0.53, 1.30) 0.424
≥9 101 (18.7%) 1.07 (0.69, 1.68) 0.753 78 (14.4%) 0.98 (0.61, 1.58) 0.939
Not recorded 42 (17.8%) 0.88 (0.53, 1.46) 0.634 34 (14.2%) 0.82 (0.48, 1.40) 0.472
Treatment
Proportion follow-up
years treated
0 (no treatment) 157 (23.6%) 1.07 (0.81, 1.39) 0.645 142 (21.3%) 0.75 (0.56, 1.02) 0.066
>0–50% treated 87 (24.9%) 1.00 68 (19.5%) 1.00
>50–80% treated 95 (18.3%) 0.64 (0.47, 0.86) 0.003 59 (11.4%) 0.43 (0.31, 0.59) <0.001
>80–100% treated 52 (11.4%) 0.35 (0.25, 0.50) <0.001 38 (8.4%) 0.24 (0.17, 0.35) <0.001
Cox Proportional Hazards Regression.
1Hazard proportionality test: p = 0.3025;
2Hazard proportionality test: p = 0.2772
CIS, Clinically Isolated Syndrome; KFS, Kurtzke Functional System; ARR, annualized relapse Rate; DMT Disease Modifying Therapy; IM Intramuscu-
lar; SC Subcutaneous; CI Confidence Interval.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 483
V. G. Jokubaitis et al. Disability in Clinically Isolated Syndrome
events. Patients exposed to DMT for between 51% and
80% of their follow-up time had a 36% (aHR 0.64, 95%
CI 0.47, 0.86) and a 57% (aHR 0.43, 95% CI 0.31, 0.59)
reduction in the rate of 3-month confirmed and 12-
month sustained disability worsening events, respectively,
compared with patients treated for >0 but ≤50%. Longer
DMT exposure was associated with even larger risk
reductions, as patients treated for greater than 80% of
their observation period had a 65% (aHR 0.35, 95% CI
0.25, 0.50) and a 76% (aHR 0.24, 95% CI 0.17, 0.35)
reduction in the rate of 3-month and 12-month worsen-
ing events, respectively, compared to patients treated for
>0 but ≤50% of their follow-up time. There was a weak
effect of a PTT ≤50% relative to patients who were
untreated (PTT of 0%) prior to a 12-month, but not a
3-month worsening event.
The identity of the first DMT commenced during fol-
low-up was co-linear with PTT and thus we ran an alter-
nate adjusted model as a sensitivity analysis substituting
PTT for DMT identity (Table 4). Interferon beta-1a intra-
muscular (IM) (aHR 0.70, 95% CI 0.53, 0.94), Interferon
beta-1b (aHR 0.58, 95% CI 0.41, 0.82), Interferon beta-1a
subcutaneous (SC) (aHR 0.51, 95% CI 0.39, 0.68), and
Glatiramer Acetate (aHR 0.59, 95% CI 0.41, 0.85) were
all associated with decreased rates of first 3-month con-
firmed worsening compared with no exposure to DMT
during follow-up (Fig. 2C). Similarly, each of these DMT
products were associated with comparable risk reduction
in 12-month sustained worsening compared to no DMT
(Table 4, Fig. 2D). Of those patients who experienced a
3-month confirmed disability worsening event, we found
that 78.3% of worsening events were preceded by a
relapse within 3 months of the worsening event in the no
DMT group, whereas, 81.6% of worsening events were
not preceded by a relapse in patients who were DMT
treated.
Patients experiencing comparatively early disability
worsening following CIS could have less opportunity and
thus lower probability of initiating treatment prior to the
worsening event relative to patients recording a confirmed
worsening later on in post-CIS follow-up. To assess
whether this biased, or otherwise influenced, the associa-
tions of treatment with worsening, we performed a sensi-
tivity analysis for time to either first 3- or 12-month
sustained worsening including time to first DMT as an
additional model covariate. Every 1-year increase in the
time to first post-CIS treatment initiation was associated
with a reduction in the risk of subsequent 3-month (HR
0.75, 95% CI 0.65, 0.87) and 12-month sustained worsen-
ing (HR 0.73, 95% CI 0.61, 0.87). However, an increasing
proportion of follow-up time on treatment remained
associated with a reduction in the risk of worsening. In a
further sensitivity analysis we showed that increasing time
to second attack was not associated with time to either
3-month (HR 0.95, 95% CI 0.88, 1.02) or 12-month
sustained worsening (HR 0.94, 95% CI 0.87, 1.02).
Table 3. Baseline demographic and clinical covariates by T2 lesion load.
Variable Level
T2 lesion load
P-value0 (n = 77) 1–2 (n = 106) 3–8 (n = 1027) ≥9 (n = 540) N/A (n = 239)
Demographics
Sex Male 14 30 306 161 60 0.1581
Female 63 76 721 379 179 0.1581
Age at onset Mean (SD) 32.3 (8.6) 33.7 (9.8) 32.5 (9.8) 33.4 (10.4) 33.3 (10.1) 0.2262
Clinical
EDSS Median (IQR) 1.5 (1, 2) 1.5 (1, 2) 1.5 (1, 2) 1.5 (0, 2) 1.5 (1, 2) 0.40293
Treatment n = 18 (23%) n = 43 (40.1%) n = 705 (68.6%) n = 407 (75.4%) n = 166 (69.5%)
Time to first DMT
from CIS onset
Median (IQR) 2.5 (1.2, 3.7) 0.9 (0.5, 1.5) 0.8 (0.4, 1.3) 0.6 (0.3, 1.1) 0.7 (0.3, 1.0) 0.0001
3
Mean (SD) 3.1 (2.5) 1.2 (1.1) 1.1 (1.2) 0.8 (0.8) 1.0 (1.2)
PTT (continuous) Median (IQR) 0.5 (0.3, 0.6) 0.6 (0.3, 0.8) 0.7 (0.5, 0.8) 0.7 (0.5, 0.9) 0.7 (0.4, 0.8) 0.00033
Mean (SD) 0.4 (0.2) 0.5 (0.3) 0.6 (0.3) 0.7 (0.3) 0.6 (0.3)
Disease
classification
at treatment start
CIS 1 (5.5%) 6 (14.0%) 124 (17.6%) 96 (23.6%) 25 (15.1%)
RRMS 17 (94.5%) 37 (86.0%) 581 (82.4%) 311 (76.4%) 141 (84.9%)
1Pearson’s v2.
2One-way ANOVA, Bonferroni’s post hoc test.
3Kruskal–Wallis.
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Discussion
Early clinical and para-clinical factors that could predict
disability outcome are of great interest in MS. Previous
studies in CIS and RRMS cohorts have proposed various
prognostic indicators.16–23 However, factors contributing
to individual disability worsening rates after CIS have not
previously been examined in a contemporary cohort.
We found that rates of 3-month confirmed and 12-
month sustained disability worsening events after CIS
onset were significantly and substantially reduced by
DMT treatment. In our study, we assessed DMT use in
two ways. Firstly, we used a contemporaneous cohort of
patients who were not treated prior to a first disability
worsening event. Secondly, to account for the fact that
clinically stable patients tend to remain untreated, and to
inherently control for treatment effect within individuals,
we assessed the cumulative proportion of time individuals
spent on treatment over the observation period. We
found a significant benefit of treatment if patients were
treated for greater than 50% of the observation period,
versus less than 50% of the time, with a further benefit if
patients were treated for greater than 80% of the observa-
tion period. This effect was more pronounced for
12-month sustained disability worsening events. Similar
results have previously been reported in a post hoc analy-
sis of an earlier trial24; where IFNb-1a IM had a more
potent effect on 12-month confirmed worsening events
than 6-month worsening events.8 Interestingly, our study
found little difference in the rate of disability accumula-
tion between those patients with a PTT of ≤50% and
those who were untreated. Two recent long-term follow-
up studies25,26 of pivotal trials also aimed to determine
the effect of cumulative treatment dose or duration on
Table 4. Predictors of 3-month confirmed and 12-month sustained disability worsening events – sensitivity model substituting first DMT identity
for PTT.
Predictor Level
3-month confirmed worsening events
(n = 391)
12-month sustained worsening events
(n = 307)
n (% of level)
Adjusted HR
(95% CI) P-value1 n (% of level)
Adjusted HR
(95% CI) P-value2
Demographics
Sex Male 110 (19.3%) 1.02 (0.82, 1.28) 0.857 83 (14.5%) 0.95 (0.73, 1.22) 0.669
Female 281 (19.8%) 1.00 224 (15.8%) 1.00
Age at CIS onset Per 10 years – 1.16 (1.05, 1.29) 0.003 – 1.16 (1.04, 1.30) 0.010
Clinical
KFS Ambulation 0 318 (17.9%) 1.00 254 (14.3%) 1.00
1+ 73 (35.1%) 1.60 (1.09, 2.33) 0.016 53 (25.5%) 1.50 (0.97, 2.30) 0.066
KFS pyramidal 0–1 242 (16.5%) 1.00 194 (13.2%) 1.00
2+ 149 (28.7%) 1.46 (1.14, 1.87) 0.003 113 (21.7%) 1.39 (1.05, 1.84) 0.023
KFS cerebellar 0–1 306 (18.5%) 1.00 243 (14.7%) 1.00
2+ 85 (25.6%) 1.06 (0.78, 1.44) 0.698 64 (19.3%) 1.33 (0.95, 1.86) 0.092
KFS bowel/bladder 0–1 342 (18.5%) 1.00 272 (14.8%) 1.00
2+ 49 (33.8%) 0.83 (0.55, 1.26) 0.388 35 (24.1%) 0.80 (0.50, 1.28) 0.349
Relapses
ARR – 1.20 (1.18, 1.21) <0.001 – 1.01 (0.97, 1.04) 0.820
MRI
T2 lesion load 0 27 (35.1%) 1.00 25 (32.5%) 1.00
1–2 26 (24.5%) 1.12 (0.64, 1.95) 0.686 22 (20.8%) 1.02 (0.57, 1.84) 0.940
3–8 195 (19.0%) 0.83 (0.55, 1.26) 0.379 148 (14.4%) 0.78 (0.50, 1.21) 0.266
≥9 101 (18.7%) 0.94 (0.60, 1.47) 0.786 78 (14.4%) 0.88 (0.55, 1.42) 0.602
Not recorded 42 (17.8%) 0.83 (0.50, 1.37) 0.466 34 (14.2%) 0.80 (0.47, 1.36) 0.416
Treatment
First DMT No DMT 153 (23.5%) 1.00 139 (21.4%) 1.00
IFNb-1a IM 76 (20.4%) 0.70 (0.53, 0.94) 0.015 56 (15.0%) 0.53 (0.39, 0.74) <0.001
IFNb-1b 43 (18.5%) 0.58 (0.41, 0.82) 0.002 33 (14.2%) 0.47 (0.32, 0.69) <0.001
IFNb-1a SC 79 (16.0%) 0.51 (0.39, 0.68) <0.001 57 (11.5%) 0.41 (0.30, 0.57) <0.001
Glatiramer Acetate 35 (16.8%) 0.59 (0.41, 0.85) 0.005 20 (9.6%) 0.33 (0.21, 0.54) <0.001
Cox proportional hazards regression. DMT, disease-modifying therapy; PTT, proportion of time on treatment; CIS, clinically isolated syndrome;
KFS, Kurtzke Functional System; ARR, annualized relapse rate; MRI, magnetic resonance imaging; IM, intramuscular; SC, subcutaneous.
1Hazard proportionality test: P = 0.2981.
2Hazard proportionality test: P = 0.1973.
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long-term disability measures. Whilst both studies had
relatively small numbers of patients and were likely
underpowered, they did reported trends in delay to dis-
ability milestones in higher dose/duration groups.25,26 In
our cohort, median disease duration at treatment initia-
tion was less than 1 year. Our results are consistent with
those of a previous study which found that patients trea-
ted within a year of RRMS onset had a 37% reduced risk
of experiencing a one-point EDSS worsening relative to
those treated more than a year after RRMS onset.12
Here, we also report that the two strongest independent
clinical predictors of individual first 3-month confirmed
worsening events are baseline dysfunction within the
pyramidal system and ARR. The effect of pyramidal
system dysfunction is consistent with previous reports
from RRMS cohorts that have identified initial motor
symptoms as a poor prognostic indicator.17,19,20,23 Our
results extend previous analyses27 by demonstrating that,
ARR is independently predictive of 3-month individual
worsening events in early MS. However, this relationship
between ARR and disability worsening requires further
examination, and will be interrogated further as our data
set matures.
Past CIS and RRMS studies have reported that older
age at onset is a poor prognostic indicator.18,20–23 Consis-
tent with these studies, we found that older age at CIS
diagnosis was an independent predictor of both 3- and
12-month sustained disability worsening events. Our
analysis shows no independent adverse effect of male sex,
consistent with previous studies.18,20,22,23
Natural history CIS and RRMS studies have consistently
found that high T2 lesion load and volume are associated
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Figure 2. Kaplan-Meier survival curves showing proportion of patients free of 3-month confirmed and 12-month sustained disability worsening
by: proportion of time on treatment (PTT; A: 3-month disability worsening; B: 12-month disability worsening) and by disease-modifying therapy
(DMT) product (C:3-month disability worsening; D: 12-month disability worsening).
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with poor prognostic outcomes.16,18,28–31 In our contem-
porary cohort, we report that T2 lesion load is, at best, a
weak predictor of the rate of disability accumulation. We
observed that patients with a high T2 lesion load were, on
average, treated earlier and longer with DMT than those
with a low lesion load. Our data therefore suggest that
DMT intervention in individuals with a high T2 load may
in part offset the adverse effect of high T2 lesion load at
onset on disability accumulation. However, this is a corre-
lation only and will need to be examined further with a
larger sample possessing greater follow-up.
There is compelling evidence from randomized con-
trolled trials (RCTs) that DMT reduce relapse rates and
T2 lesion burden in RRMS patients. However, the effect
of DMT on reduction in disability worsening, particularly
long-term confirmed worsening, is less certain. Random-
ized controlled trials of first-line therapies in CIS cohorts
have demonstrated that early treatment delays conversion
to CDMS16,32–34 and the BENEFIT extension study has
provided evidence for 3-year reductions in the risk of dis-
ability worsening in early versus late treatment groups,
however, this was not sustained at 5 years.35,36 Similarly,
long-term follow-up studies of RRMS RCTs have demon-
strated that, in general, patients in the “early” treatment
arms of these trials exhibit slower rates of disability wors-
ening compared to patients initially randomized to the
placebo arms of the respective trials.37 Studies in real-
world clinical settings have generally found that DMT
treatment results in slower EDSS worsening.38,39 However,
a recent study failed to find a significant effect of DMT
on delay to disability milestones relative to a contempo-
rary or to a historical untreated cohort.22 Patients in that
study had a mean age of 38 years and a median disease
duration of 3.0 years at treatment start, a comparatively
long delay in treatment start relative to disease duration.
In contrast, examining the hazard of 12-month sustained
worsening events in CIS and early MS, we clearly show a
marked reduction in these worsening events due to DMT
treatment. One possible explanation for these discordant
results is that treatment, when initiated in our cohort,
commenced much sooner (8 months) and at a younger
age (33.2 years) after CIS onset. Our data suggest that the
principal mechanism of action by which DMT treatment
slows the rate of disability worsening in the early phase of
MS is via the reduction in relapse-associated persistent
disability, as even in early relapsing-remitting MS,
relapse-independent worsening events were not prevented
by injectable DMT.
Strengths and limitations
The size, and cumulative follow-up available for our
cohort allowed us to analyze the independent effect of
significant variables in our multivariable models. Our
capacity to assign hazard ratios to the predictive variables
in our multivariable models now opens the possibility for
providing individualized risk prediction.
One limitation of our study is that treatment adherence
was not assessed. It is possible that treatment effects in
highly adherent patient groups could be larger than those
reported in our study. A further limitation of our study is
selection bias. As the participating centers were specialized
MS clinics, the data set contains few patients with normal
cerebral MRI scans, who are known to be at low risk of
MS conversion and disability accumulation, and the
results are not applicable to this population. However, at
the participating centers, all patients presenting within
12 months of CIS symptoms were recruited if consent
was obtained. Given the observational nature of this
study, no specific intervention was prescribed to patients,
and physicians together with their patients made treat-
ment decisions. Unlike an RCT, this study lacks randomi-
zation and may therefore suffer from indication bias.
However, the greatest treatment effect we found was that
of cumulative time on treatment. Furthermore, in our
adjusted analyses, we found that all first-line therapies
performed well, reducing rates of 12-month disability
accumulation by 47–67%, with no significant differences
between individual preparations. This is in line with a
previous report that found no difference between individ-
ual IFNb preparations in the cumulative probability of
RRMS patients remaining progression-free at 12 and
24 months.40 The intrinsic bias of RCT is that they
recruit patients with highly active disease and are there-
fore likely to find significant effects of treatment in trea-
ted versus placebo arms. In our large, perhaps more
representative patient cohort, we were nonetheless able to
demonstrate a potent treatment effect.
Clinical, pathological, and MRI findings have demon-
strated that inflammation and axonal transection occur
early in the disease course, potentially leading to irrevers-
ible disability.31,41–43 Our study provides evidence that in
a real-world clinical setting, DMT is very effective in
reducing the hazard of individual disability worsening
events if used early and consistently over an extended
period, supporting the hypothesis that treatment efficacy
is greatest in early MS. An analysis of the long-term
effects of cumulative treatment duration on 5 and 10-year
disability outcomes will be warranted in this cohort once
a sufficient follow-up period has elapsed.
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